Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

TD Cowen raised the firm’s price target on Gilead (GILD) to $95 from $85 and keeps a Buy rating on the shares. The firm updated its model ...

Gilead Sciences, Inc. (NASDAQ:GILD ... We look forward to sharing information on our plans for lenacapavir and the rest of our leading HIV portfolio at our HIV Analyst Event on December 10th. We are ...

Gilead (GILD) announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infection, ...

Gilead Sciences, Inc. (GILD) is currently at $97.23, up $5.54 or 6.04% --Would be highest close since April 27, 2016, when it closed at $100.72 --On pace for largest percent increase since June 20, ...

Gilead Sciences ( GILD) increased its growth forecast for the year on strong third quarter results, marking a shift away from ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of HIV research findings at the International ...

Operator Good afternoon, everyone, and welcome to Gilead's third quarter 2024 earnings conference call. My name is Rebecca, and I'll be your host for today. In a moment, we'll begin with our prepared ...

Foster City, Calif.-based Gilead (GILD) had net income of $1.25 billion, or $1.00 a share, for the quarter, down from $2.18 billion, or $1.73 a share, in the year-earlier period. Adjusted for one-time ...

Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ETCompany ParticipantsDaniel O'Day - Chairman, Chief ...